EF
NBIX icon

Empowered Funds’s Neurocrine Biosciences NBIX Stock Holding History

Empowered Funds’s Portfolio NBIX Stock Details NBIX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$2.33M Sell
13,827
-70,144
-84% -$10.4M 0.01% 1099
2026
Q1 		$11.1M Buy
83,971
+79,605
+1,823% +$10.6M 0.07% 344
2025
Q4 		$619K Sell
4,366
-14,458
-77% -$2.09M 0.01% 713
2025
Q3 		$2.64M Buy
18,824
+8,135
+76% +$1.1M 0.03% 780
2025
Q2 		$1.34M Sell
10,689
-1,366
-11% -$157K 0.02% 978
2025
Q1 		$1.33M Buy
+12,055
New +$1.53M 0.02% 903
2024
Q4 		– Sell
-62,052
Closed -$7.15M – 1713
2024
Q3 		$7.15M Buy
62,052
+54,114
+682% +$7.42M 0.11% 259
2024
Q2 		$1.09M Buy
7,938
+111
+1% +$15.2K 0.02% 834
2024
Q1 		$1.08M Sell
7,827
-13,211
-63% -$1.8M 0.02% 840
2023
Q4 		$2.77M Sell
21,038
-16,622
-44% -$1.91M 0.07% 406
2023
Q3 		$4.24M Buy
37,660
+20,651
+121% +$2.17M 0.12% 215
2023
Q2 		$1.6M Buy
17,009
+8,636
+103% +$844K 0.06% 485
2023
Q1 		$848K Buy
+8,373
New +$871K 0.05% 313

Other funds holding NBIX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Empowered Funds's NBIX Position: Q2 2026 in Review

Empowered Funds reduced its Neurocrine Biosciences (NBIX) stake by 84% in Q2 2026, selling an estimated $10.4M and leaving 13,827 shares worth $2.33M. The position accounts for 0.01% of the portfolio, ranked #1099.

Empowered Funds first reported a position in NBIX in Q1 2023 and has held it in 13 quarters since. The position peaked at $11.1M in Q1 2026. 775 funds tracked by Wall St. Rank hold NBIX as of Q2 2026.

  • Empowered Funds held 13,827 shares of Neurocrine Biosciences worth $2.33M as of Q2 2026.
  • Empowered Funds sold 70,144 Neurocrine Biosciences shares in Q2 2026, an estimated $10.4M.
  • Neurocrine Biosciences made up 0.01% of Empowered Funds's portfolio in Q2 2026, its #1099 holding.
  • Empowered Funds first reported a position in Neurocrine Biosciences in Q1 2023 and has held it in 13 quarters since.
  • Empowered Funds's Neurocrine Biosciences position peaked at $11.1M in Q1 2026.
  • 775 funds tracked by Wall St. Rank held Neurocrine Biosciences as of Q2 2026.

Based on Empowered Funds's 13F filing for Q2 2026, filed 17 Aug 2026.